Adeno-associated virus-mediated gene transfer in a rabbit vein graft model
Standard
Adeno-associated virus-mediated gene transfer in a rabbit vein graft model. / Kilian, Eckehard Gerd; Eifert, Sandra; Beiras-Fernandez, Andres; Daebritz, Sabine; Reichenspurner, Hermann; Reichart, Bruno.
In: CIRC J, Vol. 72, No. 10, 10.2008, p. 1700-1704.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Adeno-associated virus-mediated gene transfer in a rabbit vein graft model
AU - Kilian, Eckehard Gerd
AU - Eifert, Sandra
AU - Beiras-Fernandez, Andres
AU - Daebritz, Sabine
AU - Reichenspurner, Hermann
AU - Reichart, Bruno
PY - 2008/10
Y1 - 2008/10
N2 - BACKGROUND: Stenoses of venous grafts represent a major limitation in coronary artery bypass surgery. The use of viral vectors to facilitate over-expression of factors within the graft to promote long-term patency is a promising new therapeutic concept. One of the viral vector systems is the adeno-associated virus (AAV); a non-pathogenic single stranded DNA virus, which elicits only low immunological responses.METHODS AND RESULTS: Recombinant AAV vector coding for beta-galactosidase was produced and transferred ex vivo using intraluminal application to previously harvested rabbit internal jugular vein grafts (n = 8). The 30 min after application, an end-to-end anastomosis of each graft as a bypass to the carotid artery was performed in a previously established rabbit bypass model. X-Gal-staining of the grafts was performed after killing the animals to quantify gene expression. AAV transduction was successful in 100% of the grafts. After 30 days, beta-galactosidase gene expression could be assessed in the medial layer of the graft. Furthermore, no signs of inflammation could be detected.CONCLUSIONS: These findings suggest that recombinant AAV vectors are an alternative to the widely used adenoviral based vectors. These data support the further use of AAV vectors to overcome intimal hyperplasia after vein graft coronary artery bypass surgery.
AB - BACKGROUND: Stenoses of venous grafts represent a major limitation in coronary artery bypass surgery. The use of viral vectors to facilitate over-expression of factors within the graft to promote long-term patency is a promising new therapeutic concept. One of the viral vector systems is the adeno-associated virus (AAV); a non-pathogenic single stranded DNA virus, which elicits only low immunological responses.METHODS AND RESULTS: Recombinant AAV vector coding for beta-galactosidase was produced and transferred ex vivo using intraluminal application to previously harvested rabbit internal jugular vein grafts (n = 8). The 30 min after application, an end-to-end anastomosis of each graft as a bypass to the carotid artery was performed in a previously established rabbit bypass model. X-Gal-staining of the grafts was performed after killing the animals to quantify gene expression. AAV transduction was successful in 100% of the grafts. After 30 days, beta-galactosidase gene expression could be assessed in the medial layer of the graft. Furthermore, no signs of inflammation could be detected.CONCLUSIONS: These findings suggest that recombinant AAV vectors are an alternative to the widely used adenoviral based vectors. These data support the further use of AAV vectors to overcome intimal hyperplasia after vein graft coronary artery bypass surgery.
KW - Animals
KW - Cell Line
KW - Dependovirus
KW - Female
KW - Gene Transfer Techniques
KW - Genes, Reporter
KW - Genetic Vectors
KW - Green Fluorescent Proteins/genetics
KW - HeLa Cells
KW - Humans
KW - Jugular Veins/surgery
KW - Kidney
KW - Plasmids
KW - Rabbits
KW - Transplantation, Heterologous/methods
UR - http://www.ncbi.nlm.nih.gov/pubmed/18753702?dopt=Citation
U2 - 10.1253/circj.cj-07-0921
DO - 10.1253/circj.cj-07-0921
M3 - SCORING: Journal article
C2 - 18753702
VL - 72
SP - 1700
EP - 1704
JO - CIRC J
JF - CIRC J
SN - 1346-9843
IS - 10
ER -
